Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo

575.371 - 598.525 Dr. Bogdana Schmidt

And neoadjuvant chemo gets you 25% to 38%. There is that variability of did you get a good TUR? Was it in a location where you could have truly resected all of it? And those factors are really hard to account for. But I think to me, when I think about these things, I think that the distant metastatic potential is what I worry about the most. Right. That's why we're giving the neoadjuvant chemo.